Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 80

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 80
---
, and (iii) following the Effective Time and subject to the satisfaction or waiver of the conditions specified in the Merger Agreement on the Closing
Date but prior to the Effective Time, Enfusion, the surviving company of the Merger, will merge with and into Acquirer, with Acquirer surviving the Second Merger as a direct, wholly-owned subsidiary of Clearwater. The Merger Agreement Proposal that
Enfusion is asking its stockholders to approve is the adoption of the Merger Agreement and approval of the Mergers. If the Transactions are completed, Enfusion will cease to be publicly traded and Enfusion Common Stock will be delisted from the NYSE
and deregistered under the Exchange Act.

As described in further detail in the sections titled “Questions and Answers,”
“Summary,” “The Transactions” and “The Merger Agreement,” the Enfusion Board has unanimously approved the Merger Agreement and the Transactions. For a discussion of certain factors considered by the Enfusion Board in
determining to approve the Merger Agreement and recommend that Enfusion Stockholders vote for the Merger Agreement Proposal, see the section titled “The Transactions—Enfusion’s Reasons for the Transactions; Recommendations of the
Special Committee and the Enfusion Board.” A copy of the Merger Agreement is attached as Annex A to this Proxy Statement/Prospectus. You are urged to read the Merger Agreement carefully and in its entirety.

The Transactions are subject to the satisfaction of the conditions set forth in the Merger Agreement, including approval of the Merger
Agreement Proposal by Enfusion Stockholders at the Special Meeting. Accordingly, the approval of the Merger Agreement Proposal by Enfusion Stockholders is a condition to the obligations of Clearwater and Enfusion to complete the Transactions.

The affirmative vote, virtually or by proxy, of the holders of at least a majority of the outstanding shares of Enfusion Common Stock and
Enfusion Class B Common Stock entitled to vote on the Merger Agreement Proposal is required to approve the Merger Agreement Proposal.

THE ENFUSION BOARD UNANIMOUSLY RECOMMENDS THAT ENFUSION STOCKHOLDERS VOTE “FOR” THE MERGER AGREEMENT PROPOSAL.

50

PROPOSAL 2: THE ADJOURNMENT PROPOSAL

Enfusion Stockholders are being asked to approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there
are not sufficient votes to approve the Merger Agreement Proposal at the time of